Live Breaking News & Updates on Genfit Company Profile
Stay updated with breaking news from Genfit company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Genfit S.A. (OTCMKTS:GNFTF – Free Report) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 500 shares, a drop of 37.5% from the May 31st total of 800 shares. Based on an average daily trading volume, of 500 shares, the […] ....
French pharmaceutical company Ipsen SA (IPSEY) and late-stage biopharmaceutical company GENFIT SA (GNFT) announced Friday positive topline data from the pivotal ELATIVE Phase III trial of elafibranor in patients with primary biliary cholangitis or PBC, a rare cholestatic liver disease. ....
Genfit S.A. (EPA:GNFT – Get Rating) shares shot up 3.1% during trading on Wednesday . The stock traded as high as €4.16 ($4.47) and last traded at €4.13 ($4.44). 178,297 shares traded hands during mid-day trading, The stock had previously closed at €4.00 ($4.30). Genfit Price Performance The firm’s 50-day moving average is €3.72 and […] ....
Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis). ....
Lille ; Cambridge ; Zurich ; May 23, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the. | May 23, 2023 ....